The European Journal of Health Economics

, Volume 8, Issue 3, pp 297–300

Economic aspects of the new Spanish laws on pharmaceutical preparations

Authors

    • Department of Economics and Business AdministrationUniversidad de La Rioja
  • Juan Oliva
    • Facultad de EconómicasUniversidad de Castilla-La Mancha
  • Mariola Pinillos
    • Department of Economics and Business AdministrationUniversidad de La Rioja
  • Carmelo Juàrez
    • Department of Economics and Business AdministrationUniversidad de La Rioja
Pricing and reimbursement systems in Europe

DOI: 10.1007/s10198-007-0050-9

Cite this article as:
Antoñanzas, F., Oliva, J., Pinillos, M. et al. Eur J Health Econ (2007) 8: 297. doi:10.1007/s10198-007-0050-9

Abstract

In this article, we provide readers with a summary of the main economic features of the recently approved Spanish law regarding pharmaceutical preparations entitled the Law of Guarantees and Rational Use of Pharmaceuticals and Health Products (Law 29/2006 of July 26th). We review information on pricing, reference pricing, promotion of generic drugs, public reimbursement, patients’ contributions, and penalties. Other aspects of minor economic relevance such as the information on prices shown in the packs and the transparency on the results of clinical trials irrespective of whether these are positive or not, are not addressed in this paper. We conclude with some observations on the new horizons opened up by this new legal framework. We have not included any detailed references to the new law; we merely wish to comment on certain aspects of its application.

Copyright information

© Springer-Verlag 2007